πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9211419

Treatments of disease or disorders using nanoparticles for focused hyperthermia to increas

The Board of Regents of the University of Texas System Β· Granted Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9212212

Targeting complement factor H for treatment of diseases

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9205131

Use of IL-17D for the treatment and prevention of cancers

The Regents of the University of California Β· Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9205048

Controlled release antimicrobial compositions and methods for the treatment of otic disord

The Regents of the University of California Β· Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9198921

Non-hormonal steroid modulators of NF-ΞΊB for treatment of disease

ReveraGen BioPharma, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9200265

Anti-cocaine compositions and treatment

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9193709

1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative di

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9192628

Treatment method for relapsing-remitting multiple sclerosis

REGENEX LLC Β· Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9181577

Treatment of chronic pelvic pain syndrome

Northwestern University Β· Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9173896

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

Arrowhead Research Corporation Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9175058

Soluble immune response suppressor polypeptides and treatment of multiple sclerosis and ot

The Board of Regents of the University of Texas System Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9175062

Human soluble receptor for advanced glycation end products (sRAGE), methods of preparing h

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9169313

Method of treatment of cancers characterized by ligand-dependent activating mutations in F

Five Prime Therapeutics, Inc. Β· Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9162968

Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis

Northwestern University Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9163258

Method for the treatment of obesity

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9161936

Laquinimod for treatment of GABA mediated disorders

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9161735

Systems, compositions, and methods for local imaging and treatment of pain

The Regents of the University of California Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9157121

Method of treatment based on polymorphisms of the KCNQ1 gene

VANDA PHARMACEUTICALS INC. Β· Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9156853

AKT inhibitor compounds for treatment of cancer

ALMAC DISCOVERY LIMITED Β· Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9149489

Inhibitors of glycolysis useful in the treatment of brain tumors

The Board of Regents of the University of Texas System Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9149437

Method for treatment of solid pharmaceutical preparation prior to printing and solid pharm

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9149445

Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treat

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9149483

Methods for treatment of diseases

Galera Labs, LLC Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9149537

Compositions and methods for the treatment of traumatic brain injury

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted